γ - binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells, **wherein the bispecific antibodies are members selected from the group consisting of the following isotype combinations:**

rat-IgG2b/human-IgG1,
rat-IgG2b/human-IgG2,
rat-IgG2b/human-IgG3[oriental allotype G3m(st) = binding to protein A],
rat-IgG2b/human-IgG4;

rat-IgG2b/rat-IgG2c;

mouse-IgG2a/human-IgG3[caucasian allotypes G3m(b+g) = no binding to protein A, in the following indicated as *]

mouse-IgG2a/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2a/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human- IgG3*-[CH2-CH3]

mouse-IgG2a/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG4/rat-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2: > aa position 251]-human-IgG3*[CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge-CH2-CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG2-[hinge-CH2-CH3]

B1 Cont.

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG3-[hinge-CH2-CH3, oriental allotype]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG4-[hinge-CH2-CH3]

human-IgG1/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG2[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG2[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG2/human-[VH-CH1,VL-CL]-human-IgG2-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : ≥ aa position 251]-human-IgG3*[CH3]

mouse-IgG2b/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2b/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG4/rat-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]
rat/mouse.

2. (amended) Method according to claim 1, **in which** [characterized in that] said antibodies are selected so that they are capable of binding Fc receptor-positive cells having a Fcγ receptor I, II, or III.

3. (amended) Method according to claim 2, **in which** [characterized in that], [said antibodies are capable of binding to] **said Fcγ receptor I-positive cells are selected from the group consisting of** monocytes, macrophages, dendritic cells, ["natural killer" cells (NK cells)] and [/or] activated neutrophils.

4. (amended) Method according to claim 1, **in which** [characterized in that] said antibodies are capable of inducing **tumor** [tumour]-reactive complement-binding antibodies and thus inducing a humoral immune response.

5. (amended) Method according to claim 1, **in which** [characterized in that] said antibodies are selected to bind to the T cells via CD2, CD3, CD4, CD5, CD6, CD8, CD28 [and/] or CD44.

Sub B1 E2 Conclude

6. (amended) Method according to claim 1, ~~in which~~ [characterized in that] said antibodies are selected so that following their binding to the Fc receptor-positive cells the expression of CD40, CD80, CD86, ICAM-1 and/or LFA-3 as co-stimulatory antigens, and/or secretion of cytokins by the Fc receptor-positive cell is initiated or increased.

7. (amended) Method according to claim 1, **in which** [characterized in that] said antibodies are selected so that the secretion of IL-1, IL-2, IL-4, IL-6, IL-8, IL-12 being **cytokines** [cytokins and/] or of TNF-α **or a combination thereof** is increased.

8. (amended) Method according to claim 1, **in which** [characterized in that] said bispecific antibody is selected to be an anti-CD3 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD4 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD5 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD6 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD8 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD2 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD28 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD44 X anti-**tumor** [tumour]-associated antigen antibody.

B2

12. (amended) Method according to claim 1, **in which** [characterized in that] said trispecific antibody is selected from an anti-CD3 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD4 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD5 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD6 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD8 X

anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD2 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD28 X anti-**tumor** [tumour]-associated antigen antibody [and/] or anti-CD44 X anti-**tumor** [tumour]-associated antigen antibody.

13. (amended) Method according to claim 1, **further comprising** [characterized in that in said step c) after incubating the tumour cells with intact heterologous bispecific and/or trispecific antibodies the tumour cells charged with antibodies are prepared for reinfusion (short-term incubation)] **d) preparing the antibody-tumor cell preparation containing vaccine**.

B2 Sub E3 Amdt.

14. (amended) Method according to claim 1, **in which** [characterized in that] in said step c) [the incubation of the tumour cells with antibodies is performed together with mononucleated cells of the peripheral blood (PBMC =] peripheral blood mononucleated cells)[,] are added **and thereby activated** [or mononucleated cells are added after incubation of the tumour cells with the antibodies and the incubation is continued (long-term incubation)] **said method further comprising d) preparing a vaccine comprising the thus activated peripheral blood mononucleated cells**.

15. (amended) Method according to claim 1, **in which** [characterized in that] said **tumor** [tumour] cells are incubated with the antibodies for a period of 10 minutes to 5 hours.

16. (amended) Method according to claim 1, **in which** [characterized in that] said **tumor** [tumour] cells are incubated with the antibodies for a period of 15 minutes to 120 minutes.

17 (amended) Method according to claim 14, **in which** [characterized in that] said mononucleated peripheral cells are incubated with the **tumor** [tumour] cells and the antibodies for a period of 1 to 14 days.

18. (amended) Method according to claim 14, **in which** [characterized in that] said mononucleated peripheral cells are added in the amount of about 10^8 to 10^{10} cells.

19. (amended) Method according to claim 1, **in which** [characterized in that] said **tumor** [tumour] cells are **present** [added] in the amount of about 10^7 to 10^9 cells.

20. (amended) Method according to claim 1, **in which** [characterized in that] said bispecific [and/]or trispecific antibodies are ~~added~~ in an amount of 2 to 100 µg.

21. (amended) Method according to claim 1, **in which** [characterized in that] said treating of the **tumor** [tumour] cells in step b is performed by irradiation.

22. (amended) Method according to claim 1, **in which** [characterized in that] said bispecific [and/]or trispecific antibodies are capable of activating the Fc receptor-positive cell whereby the expression of **cytokines** [cytokins] and/or co-stimulatory antigens is induced or increased.

23. (amended) **Method for** [Use of the tumour cell containing preparation according to claim 1 in] the prevention and/**or** treatment of **a tumorous** [tumourous] disease[s], **comprising administering to an individual susceptible to such disease a tumor cell preparation prepared according to the method of claim 1**.

24. (amended) **Method** [Use] according to claim 23 for inducing an anti-**tumor** [tumour] immunity **in an individual, comprising administering to said individual a tumor cell preparation prepared according to the method of claim 1**.

25. (amended) Method **for immunizing an individual against tumor cells, comprising administering to said individual a tumor cell preparation prepared** according to **the method of** claim 1 **in which said** [for the preparation of] autologous tumor cells **used in preparing said preparation were** [treated with heterologous bispecific and/or trispecific antibodies for reinfusion into the patient or the animals from whom the autologous tumour cells have been] obtained **from said individual**.

26. (amended) A pharmaceutical composition **comprising** [containing] a **tumor** [tumour] cell preparation obtained by the method of claim 1.